OneMedNet Guides Q4 Revenue to $14M After Q3 Jump

OneMedNet Corporation (Nasdaq: ONMD) said on 6 November 2026 that it expects to report revenue of roughly $1 million for the third quarter ended 30 September 2026, a 242% increase from the second quarter and a 465% increase from the prior-year quarter. The Minneapolis-based real-world data provider also guided fourth quarter 2026 revenue to approximately $12 million to $14 million, pending anticipated customer acceptance of delivered data before quarter-end.

Context — Why OneMedNet's Q4 Revenue Guide Matters Now

The company framed the third quarter as the point where a sales funnel built through 2026 began converting into delivered product. It said revenue for the full year is weighted toward the fourth quarter, a pattern it attributes to order timing combined with scaled delivery.

That framing matters because the gap between the two periods is large. Third quarter revenue of about $1 million against a fourth quarter guide of $12 million to $14 million implies the company expects the bulk of 2026 revenue to land in a single three-month window.

OneMedNet attributes the momentum to its First-Party, Direct-from-Source data model. The company said its datasets come directly from healthcare provider partners rather than intermediaries or secondary markets, and that it de-identifies each study at the source while preserving diagnostic fidelity.

Chief Executive Aaron Green said the operational build-out is largely finished. In the company's words, the work of curating, de-identifying and delivering regulatory-grade multimodal data at scale is "substantially complete."

The company's network spans more than 2,300 sites, over 90 million patient journeys and 270 million studies, according to the release. Those figures describe scale of sourcing rather than contracted revenue.

The macro backdrop for healthcare data licensing is not addressed in the release. The company did not disclose contract values, customer names, pricing terms or the number of agreements behind the fourth quarter guide.

Data — The Numbers Behind the Q3 2026 Revenue Jump

Metric	Figure
Q3 2026 preliminary revenue	~$1 million
Change vs Q2 2026	+242%
Change vs Q3 2025	+465%
Q4 2026 revenue guidance	~$12M to $14M
Network sites	2,300+
Patient journeys	90 million+
Studies	270 million+

The 242% sequential increase and the 465% year-over-year increase both trace to a small base. A 465% gain from the prior-year quarter implies third quarter 2025 revenue of roughly $177,000, derived from the company's own percentage. A 242% gain from the second quarter implies roughly $292,000 in the June quarter.

The fourth quarter guide sits between 12 and 14 times the third quarter figure. The company tied that step-up to customer acceptance of delivered data by quarter-end, which it described as anticipated rather than contracted.

The release gives no comparable peer figures, no sector benchmark and no margin data. It also gives no full-year 2026 revenue total, so the implied contribution of the first half cannot be calculated from the release alone.

The third quarter number is preliminary. OneMedNet said results remain subject to finalisation and adjustment in its Quarterly Report on Form 10-Q for the period, which it expects to release by 16 November 2026.

Analysis — What OneMedNet's Guidance Means for Healthcare Data Tickers

The company's positioning places it alongside other healthcare data and imaging analytics names, but the release names no peers and gives no comparative valuation or revenue multiple. Any peer read-across would require figures the release does not contain.

The central risk sits in the word "pending." Fourth quarter revenue depends on customers accepting delivered data by quarter-end. Acceptance timing is a control point held by the buyer, not the seller, and the company itself lists timing of customer acceptance and data delivery among its stated risks.

A second consideration is the shape of the year. A business that recognises most of its annual revenue in one quarter will show volatile sequential comparisons, which can complicate how the market reads each print.

The company's stated differentiator is provenance. Data sourced directly from provider partners, de-identified at the source, is positioned for regulatory submissions and AI model training where audit trails matter. That is a compliance argument, not a pricing argument, and the release offers no evidence on pricing.

Positioning is difficult to assess from the release. It discloses no share count, no cash balance, no debt and no institutional ownership, so no flow conclusion can be drawn from the document.

What the release does establish is that management expects the funnel to convert. Whether that conversion is recognised in the fourth quarter or slips into the following period is the variable the guidance explicitly conditions on.

Outlook — What to Watch After OneMedNet's Q4 Guidance

The first catalyst is the Form 10-Q for the quarter ended 30 September 2026, which the company expects by 16 November 2026. That filing should finalise the preliminary third quarter figure and may disclose customer concentration and contract detail the release omits.

The second is confirmation of customer acceptance of delivered data before the end of the fourth quarter. The company tied its $12 million to $14 million guide directly to that event.

The third is any update to the sales funnel. The company said the funnel grew substantially over 2026 but gave no backlog figure, no pipeline value and no booking metric.

The release names no price levels, no moving averages and no valuation thresholds. The 10-Q is the only dated event the company provides.

Frequently Asked Questions

What does OneMedNet's Q4 2026 revenue guidance actually depend on?

The guidance of approximately $12 million to $14 million is conditioned on customers accepting data the company has delivered before the quarter ends. The company described this acceptance as anticipated, not guaranteed, and lists the timing of customer acceptance and data delivery among the risks that could affect results. If acceptance slips past year-end, revenue recognition timing would shift accordingly.

Why is OneMedNet's third quarter revenue so small compared with its fourth quarter guide?

The company said 2026 revenue is weighted toward the fourth quarter because of order timing combined with scaled delivery. Its sales funnel grew through the year, and delivery at scale began in the third quarter. The fourth quarter guide is roughly 12 to 14 times the preliminary third quarter figure, so the company expects most of the year's revenue in one period.

Is OneMedNet's third quarter 2026 revenue figure final?

No. The company described the approximately $1 million figure as preliminary and subject to finalisation and adjustment in its Quarterly Report on Form 10-Q for the quarter ended 30 September 2026. OneMedNet said it expects to release that filing by 16 November 2026. Investors should treat the preliminary number as subject to revision.

Bottom Line

OneMedNet's fourth quarter hinges entirely on whether customers accept delivered data before year-end.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.